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ABSTRACT
THE EFFECTS OF ANGIOGENIC GROWTH FACTORS ON MESENCHYMAL
STEM CELL PROLIFERATION AND DIFFERENTIATION
TO VASCULAR CELL FATES
by William D'Angelo
May 2013
Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into
several cell lineages, including mural cells, which surround and support blood vessels,
and possibly endothelial cells, which form the blood vessel walls. In this study, we
investigated the effects of basic fibroblast growth factor (bFGF) and vascular endothelial
growth factor (VEGF), two of the best-characterized angiogenic factors, on MSC
proliferation and differentiation. We hypothesized that treatment with these two factors
could inhibit mural cell character and promote differentiation toward an endothelial cell
fate. C3H/10Tl/2 cells (a line of MSCs derived from mouse embryonic tissues) were
treated with bFGF and VEGF, either alone or in combination, over a 9-day course. The
effects on cell proliferation and cell type-specific marker expression were determined by
cell cycle analysis, quantitative real-time PCR (RT-qPCR) analysis, and flow cytometry.
bFGF significantly stimulated MSC proliferation and inhibited expression of mural cell
markers, with no apparent effect on endothelial marker expression. VEGF alone or in
combination with bFGF had no significant effects on expression of mural cell or
endothelial cell differentiation markers. We conclude that these angiogenic factors,
although critical in maintaining the properties of endothelial cells, are not sufficient to
promote C3H/10Tl/2 cell differentiation to endothelial cells.
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CHAPTER I
INTRODUCTION
Vascular Development

Vessel Structure
The mammalian vasculature is an intricate organ that supplies all cells of the body
with necessary oxygen and nutrients and is able to sense and respond to dynamic tissue
needs. Blood vessels are composed of three main parts: a layer of endothelial cells that
makes up the luminal surface of the vessel; a layer of mural cells, which surround the
vessel and function in regulating vessel diameter to control blood flow, stabilizing
contacts between endothelial cells, and secretion of extracellular matrix components; and
a basement membrane, a layer of collagen and other connective tissue proteins that
provides structural support and participates in signaling with endothelial and mural cells.
In large vessels, vascular smooth muscle cells (vSMCs) make up the mural cell

component and are found in a continuous abluminal sheath separated from the vessel
endothelium by the basement membrane. In capillaries, the microvessels where gas and
nutrient exchange occurs, the mural cells are pericytes, which are embedded within the
basement membrane and make focal contacts with multiple endothelial cells. Pericyte
coverage of capillaries is discontinuous and variable, reportedly ranging between 10%
and 50% depending on the tissue (Shepro & Morel, 1993). Pericytes are positioned on the
vessel to minimally inhibit gas and nutrient exchange with the tissue, and their variable
abundance probably reflects different functional requirements of capillary beds in
different tissues (Gerhardt & Betsholtz, 2003).
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Vasculogenesis and Angiogenesis
Vascular development proceeds through two related processes: vasculogenesis,
the initial, de novo formation of vessels; and angiogenesis, the sprouting of new vessels
outward from the walls of already-formed vessels. Vasculogenesis occurs mainly during
embryonic development, when multipotent vascular progenitor cells (hemangioblasts) in
the yolk-sac differentiate to so-called blood islands containing endothelial and
hematopoietic precursors. As these precursors differentiate, blood islands coalesce and
organize into the vessels of the primary vascular plexus.
After the primary vascular plexus is formed by vasculogenesis, further vascular
development proceeds via the process of angiogenesis, as new vessels sprout and grow to
fill out the primitive vasculature, which is then subjected to pruning and remodeling.
Unlike vasculogenesis, angiogenesis continues to some extent into adulthood, for
instance during wound healing. Sprouting angiogenesis occurs when a growth factor
signal (for example, vascular endothelial growth factor, VEGF) activates endothelial cells
of an existing vessel wall, as illustrated in Figure 1. Before the new sprout can form, the
basement membrane must be degraded to allow an opening for new cells to grow into.
Activated endothelial cells begin to produce proteases that break down basement
membrane proteins. If many or all of the endothelial cells in a given area of a vessel
were to become activated and migratory, the extant vessel would be destroyed,
interrupting local circulation. So to prevent vessel destruction and disorganized growth, a
mechanism of lateral inhibition by Notch signaling selects a single endothelial cell to
adopt the invasive tip cell phenotype and migrate toward the VEGF gradient (Gridley,
2007). As tip endothelial cells continue to migrate along the growth factor gradient, the
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trailing stalk cells proliferate and form into a tube structure to make the walls of the new
vessel. The final stage of vessel growth involves the recruitment of mural cells which
surround the vessel, stabilize contacts between endothelial cells, and secrete a new
basement membrane to result in a mature vessel.
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Figure 1. Angiogenic process and proposed role of mesenchymal stem cells. (a)
Endothelial cells are activated and begin migrating toward a growth factor gradient. (b)
A specialized tip cell leads the vessel sprout while trailing stalk cells proliferate to form
new vessel walls. A primitive vascular network is formed (c), followed by recruitment of
mural cells to stabilize the vessel (d), possibly differentiated from mesenchymal stem
cells (MSCs). Alternatively, MSCs may differentiate to endothelial cells and incorporate
directly into the vessel walls (figure adapted from Wood, Kamrn, & Asada, 2011).
Roles of Mural Cells in the Vasculature
While endothelial cell behavior has been extensively studied for many years,
mural cells have received comparatively little attention. However, these cells have
several important roles in angiogenesis and vessel maintenance and function. Several
studies have shown that pericyte investment of new vessels is concurrent with vessel
maturity (von Tell, Armulik, & Betsholtz, 2006) and is apparently necessary for vessel
stability, as animal models with faulty pericyte recruitment show vessel regression and
defects in circulation (Hall, 2006). The chronically inflamed, malformed, and leaky
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vasculature characteristic of tumors is often marked by a decrease in pericyte coverage
(Hall, 2006), and pericyte loss is one of the early events in diabetic retinopathy (Hammes,
2005).
The presence of pericytes is thought to stabilize vessels by several different
mechanisms. One method of pericyte/endothelium interaction is through paracrine
signaling. For example, knockout studies have shown that PDGF-B production by
endothelial cells and PDGFR-P expression by pericytes are required for pericyte
recruitment to new vessels (Enge et al., 2002), and TGF-P production by vesselassociated pericytes is thought to induce differentiation of endothelial cells and maintain
their quiescence (Armulik, Abramsson, & Betsholtz, 2005). The angiopoietin/Tie-2
signaling loop between pericytes and endothelial cells is also involved in vessel
maturation and stability, as evidenced by embryonic death due to cardiovascular failure
in animals where this pathway is inactivated (Suri et al., 1996).
Direct cell-cell contacts are another important mechanism for proper vessel
maintenance and function. Peg-and-socket junctions between endothelial cells and
pericytes are characterized by the presence of the cell-cell adhesion protein N-cadherin.
Administration of N-cadherin-blocking antibodies results in severe vascular defects
characterized by inefficient pericyte-endothelial contact, and interestingly, disrupted
endothelial-endothelial contacts (Gerhardt, Wolburg, & Redies, 2000). It seems that Ncadherin signaling upregulates endothelial expression VE-cadherin (the major cell
adhesion molecules between endothelial cells)- thus pericyte-endothelial contacts
directly promote stable connections between endothelial cells to maintain vessel integrity
(von Tell et al., 2006).
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Pericytes also have indirect effects on vascular stability through their secretion of
basement membrane components. Interactions between endothelial cells and extracellular
matrix proteins are largely mediated through integrin signaling. Integrins are cell-surface
receptors that can bind matrix components such as collagens, laminins, and fibronectin.
Integrins have an intracellular domain that can interact with several signaling proteins in
the cytoplasm, thus signaling to the cell information about the extracellular environment.
Because different combinations of integrin a. and p subunits can bind different matrix
substrates, the sum of the integrin signals that a cell receives allows it to sense its
surroundings in detail. The importance of these signals in vessel stability and endothelial
quiescence has been shown in many studies (Stratman & Davis, 2012).
Angiogenic Factors
Although many growth factors, cytokines, and other regulatory molecules are
involved in the regulation of blood vessel formation and maintenance, bFGF and VEGF
are by far the two best studied growth factors that are pivotal for vasculogenesis and
angiogenesis. The following sections briefly review their model of action and signaling
pathways that they activate.
bFGF Signaling

Basic fibroblast growth factor (bFGF) or FGF2 is a pleiotropic growth factor
belonging to the fibroblast growth factor superfamily, which contains 22 members (in
humans) organized into 7 subfamilies. bFGF was originally isolated from the bovine
pituitary gland in 1974 and characterized as a potent mitogen for fibroblasts and an
inducer of angiogenesis in vivo (Ornitz, 2000). The bFGF protein ranges from 18-34 kDa
depending on the translation start site. High and low molecular weight (HMW and LMW)
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isoforms are reported to localize to different intracellular compartments and may lead to
different physiological effects (Liao et al. , 2009; Reiland & Rapraeger, 1993; Dow &
White, 2000). While HMW bFGF is thought to localize mainly to the nucleus, LMW
bFGF is found in both the cytosol and the nucleus, as well as in the extracellular matrix
(Liao et al., 2009).
There are four high-affinity cell surface FGF receptors (FGFRl-4), which belong
to the receptor tyrosine kinase (RTK) family. FGF receptors are subject to alternative
splicing to generate different isoforms, each with different ligand binding specificities,
expression patterns, and physiological effects. These receptors share the same general
structure, including two or three extracellular immunoglobulin-like (lg-like) repeat
domains which determine ligand-binding specificity, an acid box region, a heparin
binding motif, a single transmembrane domain, and an intracellular split tyrosine kinase
domain near the C-terminal end (Eswarakumar, Lax, & Schlessinger, 2005).
Ligand binding induces receptor dimerization and autophosphorylation of seven
tyrosine residues in the intracellular tyrosine kinase domain, resulting in its activation
(Vecchione et al., 2007). Signaling pathways activated downstream of the receptor are
shown in Figure 2. Phosphorylated tyrosine residues of the receptor serve as binding
sites for downstream signal proteins, including the adapter protein FRS2a, which recruits
Grb2 and Shp2 via their SH2 domains. The FRS2a/Grb2/Shp2 complex recruits SOS,
which then activates Ras, leading to downstream activation of the MAPK pathways
ERKl/2, JNK, and p38. Grb2 can also complex with Gabl , which then recruits PI3K to
activate the Akt pathway. Phospholipase C-gamma (PLC-y) can also bind to the activated
FGFR, leading to DAG and IP3 production, intracellular Ca2+ release, and PKC activation
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(Eswarakumar et al., 2005). Activation of these pathways can alter gene expression to
regulate different cellular events, such as cell proliferation and differentiation.

In addition to FGFRs, bFGF is also known to bind heparin and heparan sulfate
proteoglycans (HSPGs) such as perlecan and syndecan. HSPGs are found on the surface
of most cells and are major components of the extracellular matrix. Evidence suggests
that these ECM proteins are essential for efficient receptor activation, as cells that cannot
produce HSPGs require exogenously added heparin for FGF signaling to occur (Omitz et
al. , 1992). It is thought that HSPGs facilitate signaling by stabilizing transient binding
between a single FGF molecule and receptor long enough for receptor dimerization to
form an active signaling complex (Omitz, 2000).
Besides their direct role in receptor activation, HSPGs also sequester secreted
bFGF in the basement membrane by preventing its diffusion and protecting from thermal
degradation and proteolysis (Omitz, 2000). The presence of bFGF in the basement
membrane has implications for angiogenesis: as activated endothelial cells secrete
proteases to degrade the basement membrane, bFGF (as well as other matrix-bound
growth factors) is released to regulate endothelial cell and mural cell behaviors.
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Figure 2. Signaling pathways activated by bFGF. Ligand binding is facilitated by
extracellular heparan sulfate proteoglycans (HSPGs) and induces receptor dimerization,
autophosphorylation, and the assembly of a functional intracellular signaling complex
that can activate several downstream signaling pathways, including PLC-y/PKC,
PI3K/Akt, and the MAPK pathways (figure from Lanner & Rossant, 2010), which
coordinately regulate different cellular events.
VEGF Signaling

Vascular endothelial growth factor (VEGF) is a family of growth factors with
major roles in angiogenesis. VEGF-A is the best characterized, but five related proteins
have been identified (VEGF-B, C, D, and E, as well as placenta growth factor, PlGF).
VEGF-A is a well-characterized inducer of angiogenic sprouting and endothelial cell
proliferation, migration, and survival (Greenberg, 2008). VEGF-A is crucial for proper
vasculogenesis; the loss of even a single VEGF-A allele results vascular malformation
and embryonic death (Carmeliet et al., 1996). Additionally, three transmembrane
receptor tyrosine kinases (VEGFRl-3) have been described. While VEGF-A binds to
VEGFR-1 and -2, VEGFR-2 is responsible for most of the angiogenic effects of VEGF
signaling (Ball, Shuttleworth, & Kielty, 2007). VEGFR-1 may serve as a decoy or sink
for VEGF-A (Fong, Rossant, Gertsenstein, & Breitman, 2002).
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VEGF receptors function similarly to other RTKs: ligand binding induces
receptor dimerization and autophosphorylation of tyrosine residues in the cytoplasmic
domain, followed by endocytosis of the receptor/ligand complex into a signaling
endosome (Matsumoto & Mugishima, 2006). The downstream signaling pathways in
endothelial cells have been well-characterized (Fig. 3). Phosphorylated tyrosines serve as
binding sites for PLC-y, Grb2, and Shb. PLC-y activation leads to production of DAG
and IP3, which leads to intracellular Ca2+ release and PKC activation. PKC activation
leads to activation of the MEKIERK pathway via Raf and stimulates cell proliferation.
Binding of Grb2 and Shb adapter proteins to activated VEGFRs leads to downstream p38
and PI3K activation, cytoskeletal reorganization, and migration (Matsumoto &
Mugishima, 2006). Additionally a complex composed of VEGF-NVEGFR2 with VEcadherin,

~-catenin,

and PI3K is essential for endothelial cell survival (Carmeliet et al. ,

1999).
VEGF is produced by cells in response to hypoxia, or low levels of oxygen, via a
mechanism involving the transcription factor hypoxia-inducible factor-1 (HIF-1). At
normal oxygen levels, the a subunit of HIF-1 is quickly hydroxylated, which flags it for
ubiquitination and degradation by the proteasome. But the enzyme that hydroxylates
HIF-1a cannot function under hypoxic conditions, resulting in increased stability of HIF1a, which forms a dimer with the constitutively produced~ subunit and binds to
promoters of responsive genes, including the VEGF gene, stimulating its transcription
and leading to angiogenesis (Neufeld, Cohen, Gengrinovitch, & Poltorak, 1999).
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Figure 3. Signaling pathways activated by VEGF. VEGF binding induces receptor
dimerization, autophosphorylation, and the assembly of a functional intracellular
signaling complex that can activate several downstream signaling pathways, including
PLC-y/PKC, PI3K/Akt, and the MAPK pathways (figure from Sigma-Aldrich,
http://www.sigmaaldrich.com/life-science/cell-biology/learning-center/pathway-slidesand/signaling-pathways.html).

Mesenchymal Stem Cells (MSCs)

Stem Cells
The term, stem cell, is applied to cells with two main characteristics: self-renewal
and multipotency. Self-renewal refers to a cell's ability to reproduce itself without
differentiation, while multipotency is the ability to differentiate into multiple cell types
when induced. There are several different types of cells that fall under the category of
stem cells, and each type has its own unique properties, such as characteristic
differentiation capacity, tissue of origin, marker expression profiles, morphology, and cell
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cycle control mechanisms. Stem cells can be classified into two broad types, embryonic
stem cells and adult stem cells. These categories are briefly discussed below.
Embryonic stem cells (ESCs) are cells derived from the inner cell mass (ICM) of
a blastocyst, an early stage of embryonic development. ESCs are pluripotent, or able to
differentiate into all cell types from all three germ layers (ectoderm, mesoderm,
endoderm). The discovery and isolation of ESCs has generated tremendous excitement
over their potential use in regenerative medicine. However, several barriers to clinical
implementation remain, including ethical concerns about the destruction of embryos
during harvest and questions about the purity, tumorigenic potential, and irnmunogenicity
of ESC-derived cells. For these reasons, the greatest contributions of ESCs to date have
been in the field of basic research, such as cell and developmental biology (Wobus &
Boheler, 2005).
Self-renewing and multipotent cells that are derived from post-blastocyst tissues
are collectively called adult stem cells. Hematopoietic stem cells, which can differentiate
into all blood cell types, were the first to be discovered when they were isolated from
bone marrow aspirates (Till & McCulloch, 1961). Since that time, stem cells have been
isolated from a wide variety of postnatal tissues, such as the brain, skeletal muscle,
cardiac muscle, intestine, skin, dental pulp, and fat. It seems that most if not all tissues
and organs contain rare, relatively undifferentiated progenitor cells that are normally
quiescent but can differentiate to mature cells of that tissue when induced. For instance,
neural stem cells give rise to neurons and glial cells in the central nervous system, and
stem cells in the skin and intestines differentiate to replace epithelial cells that are
continuously ageing. Additionally, recent findings suggest that some adult stem cells
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have a higher plasticity of differentiation potential than was originally appreciated. For
example, mesenchymal stem cells have been reported to differentiate into nonmesodermal lineages such as neurons (mesoderm to ectoderm) (Jiang et al., 2002), and
neural stem cells have been reported to differentiate to hematopoietic progenitors
(ectoderm to mesoderm) (Bjomson, Rietze, Reynolds, Magli, & Vescovi, 1999).
Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are multipotent cells that are characterized by
their ability to differentiate into cells of various mesodermal tissues, such as bone,
cartilage, and fat. Physiologically, MSCs are thought to serve as a reservoir for the
replenishment of injured or diseased mesodermal cells (Minguell, Erices, & Conget,
2010). Other possible roles include maintenance of microenvironment via production of
growth factors, cytokines, and extracellular maintenance components, and regulation of
immune cell function (Uccelli, Moretta, & Pistoia, 2008). In vitro, they are easily
cultured, maintained, and induced to differentiate to several functional phenotypes. For
these reasons, MSCs have attracted attention for their potential roles in medicine and for
their utility as tools for development and differentiation studies.
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Figure 4. Typical differentiation potential of MSCs. The classic differentiation potential
of MSCs includes chondrocytes, osteocytes, and adipocytes. In addition, MSCs from
various sources have also been induced to differentiate to myocytes, astrocytes, mural
cells, fibroblasts, and endothelial cells (figure from Grassel 2007).

MSCs may not comprise a single homogeneous population, and cells with the
hallmarks of MSCs have been isolated from different tissues and developmental stages.
Similar populations have been variously described as fibroblast colony forming units
(Castro-Malaspina et al. , 1980), mesenchymal stem cells, bone marrow stem cells,
marrow stromal cells, mesenchymal adult progenitor cells, and marrow-isolated adult
multilineage inducible cells (Minguell et al., 20 10).
In vitro, MSCs are plastic-adherent and form proliferative colonies. Cells have a
fibrob last-like morphology with long thin cytoplasmic processes (Pinney & Emerson,
1989), and are sensitive to post-confluence inhibition of growth (Reznikoff, Brankow, &
Heidelberger, 1973). Many profiles of molecular marker expression have been described,
and it seems not all MSCs display all the markers all the time. However, as part of the
minimum criteria for MSCs proposed by the Mesenchymal and Tissue Stem Cell
Committee of the International Society for Cellular Therapy, MSCs should express
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CD105, CD73, and CD90, and should not express CD45, CD34, CD14, CDllb, CD79a,
CD19, or HLA-DR (Dominici et al., 2006). MSCs have been classically described as able
to differentiate to osteoblasts, chondrocytes, and adipocytes (Pinney & Emerson, 1989).
In addition, some papers report differentiation to smooth muscle/mural cells, skeletal

muscle, cardiac muscle, endothelial cells, and neural cells (Minguell et al., 2010; Wang,
et al., 2010; Woodbury, Schwarz, Prockop, & Black, 2000). MSCs are distinct from
hematopoietic stem cells (HSCs) and thus do not differentiate into blood cells.
MSC isolation is usually achieved using either the colony-forming unit-fibroblast
(CFU-f) assay or by fluorescence-activated cell sorting (FACS). First, tissue samples
(often bone marrow aspirates) are separated using density gradient centrifugation. Cells
at the plasma-solution interface are collected and then subjected to one of the above
assays. The CFU-f assay involves plating of the primary cells in a tissue culture dish and
washing away non-adherent cells to obtain adherent, colony-forming cells with a
fibroblast-like morphology. These cells typically display accepted MSC markers and trilineage potential (Oswald, 2004). For isolation by FACS, primary cells are incubated
with fluorophore-tagged antibodies that bind to consensus MSC markers, and then a flow
cytometer is used to separate cells with the desired marker expression profile. For
instance, Crisan et al. used this technique to sort CD146+/CD34- CD45- CD56perivascular cells from several tissues. The sorted cells showed characteristic MSC
morphology and differentiation potential (Crisan et al., 2008).
Differences in tissue source, developmental stage, and reported molecular marker
expression profile, as well as variation in isolation, culture, and differentiation protocols,
have led to ambiguity about the in vivo origin and identity of MSCs. That putative MSCs
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have been isolated from many different vascularized tissues may be evidence of a
perivascular origin (Caplan, 2008). A study by Crisan et al. characterized a population of
perivascular cells in the microvasculatures of various tissues that displayed canonical
MSC markers and tri-lineage differentiation capability, which implies that pericytes and
MSCs are closely related, if not equivalent (Crisan, et al., 2008). It is possible that
MSCs/pericytes play different physiological roles under different conditions. In stable
adult tissues, these cells may function as pericytes, maintaining integrity and homeostasis
in blood vessel walls. During early development or after tissue damage, the same cells
might be induced to activate more MSC-associated functions , such as migration to an
area and subsequent differentiation to a required cell type, deposition of extracellular
matrix (ECM) components, or regulation/modulation of the behavior of other cells
through the release of paracrine factors (Caplan, 2008).

C3H/10Tl/2 Cells
C3H/10Tl/2 cells are a clonal cell line derived from 14-17 day C3H mouse
embryos by Reznikoff et al. (1973). Although the tissue of origin is unknown, lOTl/2
cells display the characteristic marker expression and differentiation potential of typical
mesenchymal stem cells. In vitro, they are plastic-adherent, sensitive to contact
inhibition, and display a fibroblast-like morphology when subconfluent. In confluent
cultures they take on a more rounded appearance, and cultures have a characteristic
cobblestone appearance. Their genome is hypertetraploid for mice, with a chromosome
number of 81 (normal diploid number is 40). They are non-tumorigenic when injected
into mice, and do not express C-type retroviruses (Reznikoff et al., 1973; Pinney &
Emerson, 1989).
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C3H/10Tl/2 cells have been differentiated to several cell types: most commonly
the three MSC hallmark lineages of adipocytes, chondrocytes, and osteocytes (Pinney &
Emerson, 1989), but also to skeletal muscle (Kubo, 1991) and pericytes/smooth muscle
cells (Proweller, Pear, & Parmacek, 2005). C3H/10Tl/2 cells express smooth
muscle/pericyte markers, and have been used in coculture studies of angiogenesis to
model mural cells (Ding, Darland, Parmacek, & D'Amore, 2004). Additionally, these
cells have been reported to differentiate to endothelial cells induced by shear stress
(Wang et al., 2005) or angiogenic factors (Wang et al., 2010) as induction stimuli.

Effects of Angiogenic Factors on MSCs
Basic fibroblast growthfactor. bFGF has been shown to stimulate proliferation in
several cell types, including endothelial cells and MSCs (Martin, 1997; Tsutsumi, 2001;
Ramasamy, et al. , 2012). In oligodendrocyte precursor cells, bFGF was found to
stimulate proliferation by promoting cyclin D1 transcription by MAPK pathway
activation, and by suppressing levels of p27, a CDK inhibitor (Frederick, Min, Altieri,
Mitchell, & Wood, 2007; Frederick & Wood, 2004; Li & DiCicco-Bloom, 2004). c-Jun
pathway activation by activated FGFR is important for cyclin D1 induction (Reilly &
Maher, 2001). Several studies have found that MSCs do not lose their differentiation
potential after bFGF-induced proliferation (Lee, 2012; Tsutsumi, 2001) and one study
found that osteogenic differentiation was actually increased after bFGF-induced
expansion compared with untreated controls (Martin, 1997), suggesting that bFGF may
prime cells for subsequent differentiation.
bFGF has also been shown to inhibit mural differentiation of MSCs. Papetti,
Shujath, Riley, & Herman (2003) showed that TGF-~-mediated expression of SMC genes
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in retinal pericytes is interrupted by treatment with bFGF. Another group found similar
results in C3H/10Tl/2 cells, and reported that bFGF-mediated suppression of SMC genes
was dependent on MEKIERK pathway activation (Kawai-Kowase, 2004).
Aside from its effects on MSC proliferation and differentiation, bFGF can also
control migration of MSCs. Schmidt et al. (2006) found that bFGF at low doses was
attractant for bone marrow-derived MSCs, while at high doses MSCs were repelled.
They also found that these behaviors were mediated through Akt/PKB pathway activation
(Schmidt et al., 2006).

Vascular endothelial growth factor. VEGF has been reported to induce
endothelial differentiation of bone marrow MSCs (Oswald, 2004) and osteogenic
differentiation of dental pulp MSCs (D'Alimonte et al., 2011). It has also been reported
that VEGF in combination with bFGF can stimulate C3H/10Tl/2 cell endothelial
differentiation (Wang et al., 2010). VEGF also stimulates proliferation in dental pulp
MSCs (D'Alimonte et al., 2011) and bone marrow MSCs in a MEKIERK dependent
manner (Kong et al. , 2010). Although MSCs do not express VEGF receptors (Wang et
al., 2010; Ballet al., 2007), it has been shown that VEGF can stimulate PDGF receptors,
which are expressed in MSCs (Ball et al., 2007). The contribution of the PDGF receptors
to VEGF-mediated differentiation of MSCs is unknown.

18
CHAPTER II
OBJECTIVE AND SIGNIFICANCE
Mesenchymal stem cells have generated much excitement in the field of
regenerative medicine. MSCs can differentiate to several lineages, and their tissue
regenerative properties have been well-documented in animal models (Wakitani et al.,
1994; Wakitani et al., 2007). They can home to sites of injury, and not only differentiate
into required cell types but can also promote restoration of injured tissues by production
of microenvironmental components (Haynesworth, Baber, & Caplan, 1996) and the
suppression of inflammation (Uccell et al., 2008). MSCs can be isolated from a wide
variety of sources, and they are easily cultured and expanded in vitro, raising the
possibility of autologous transplantation (the use of a patient's own stem cells to treat
disease, reducing the risk of immune rejection). Although embryonic stem cells have a
greater potential for differentiation than MSCs, ESCs are also harder to isolate and
maintain in culture. Additionally, it has proven difficult to direct ESC differentiation to
specific cell types and to obtain large quantities of pure ESC-derived cells, which makes
MSCs an attractive alternative. Clarifying the potential for differentiation to various cell
lineages and the mechanisms involved is necessary for establishing the generation of
clinically useful MSC-derived cells.
Because pathological angiogenesis is a contributing factor to a wide range of
diseases, a great amount of effort has been devoted to understanding the mechanisms of
this process. However, the contribution of MSCs to angiogenesis is still incompletely
characterized. The similarities between putative MSCs and mural cells have been shown
in detail, and it seems likely that MSCs can take part in angiogenesis by differentiating to
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mural cell phenotypes. But a few studies indicate that MSCs also have the potential to
become endothelial cells and incorporate into new vessel walls. Growth factor signaling
is a major regulator of cell behavior during angiogenesis. The objective of this study is to
clarify the effects of angiogenic growth factors on C3H/10Tl/2 cell differentiation to
vascular cell types. Based on our preliminary observations of the individual effects of
bFGF and VEGF, the current research proposes a more efficient method for the
differentiation of C3H/10Tl/2 cells to an endothelial lineage than that used by Wang et
al. (2010). Optimizing this method would potentially provide a new source for efficient
generation of endothelial cells and a model for the study of endothelial induction, and
could shed light on the participation of MSCs in the angiogenic process.
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CHAPTER III
METHODS
Mesenchymal Stem Cell Culture
The cells used in this study were C3HI10Tl/2 cells, described by Reznikoff et al.
(1973). Cells were cultured in 10% FCS MEMa in a 37°C humidified incubator with 5%
C02 atmosphere. For differentiation experiments, cells were seeded to 6-well culture
dishes at low density ( -2000 cells/cm2) and growth factors (VEGF and bFGF, alone or in
combination) were added to the medium at concentrations ranging from 5-10 ng/mL.
Medium was refreshed every 3 days.
HoxB5 Stable Transfection
Cells were transfected with pcDNA3-HoxB5 plasmid using Lipofectamine
(Invitrogen) transfection reagent. In a 1.5 mL microcentrifuge tube, 0.5 mL of OptiMEM (Invitrogen) and 5 )lg of pcDNA3 plasmid DNA were incubated for 5 minutes at
room temperature. In another tube, 0.5 mL Opti-MEM and 20 J.!L Lipofectamine were
also incubated for 5 minutes at room temperature. These two mixtures were combined
and further incubated at room temperature for 25 minutes before being added to the cells.
After 48 hours, G418 was added to the culture dish at 375 J..lg/mL to eliminate growth of
untransfected cells. After two weeks, cells that survived were stably transfected, which
was confirmed by RT-qPCR analysis for HoxB5.
Spectrophotometric Analysis of Cell Number
Treated C3H/10T1/2 cells were fixed with methanol for 15 minutes, then washed
three times with PBS, followed by staining with toluidine blue (TB) for 30 minutes.
Cells were rinsed with tap water to remove excess TB and allowed to air dry. The TB was
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extracted from the cells by a 2% SDS wash. Optical density was measured with a BioTek Instruments ELX 800 microplate reader and KCjunior software.
RNA Extraction
Total RNA was extracted using Tri-reagent (Sigma). Medium was aspirated from
the culture dish and Tri-reagent was added, followed by 3 minutes of shaking. The
sample was transferred to a 1.5 mL microcentrifuge tube and stored at -70°C. Chloroform
(0.2 mL per mL ofTri-reagent) was added, then samples were vortexed for 15 seconds
and incubated at room temperature for 10 minutes. Next, samples were centrifuged at
10000 rpm for 10 minutes at 4°C. The aqueous supernatant containing RNA was
transferred to a new 1.5 mL microcentrifuge tube and an equal volume of isopropyl
alcohol was added. After a 10 minute incubation at room temperature, samples were
centrifuged at 12000 rpm for 15 minutes at 4°C to precipitate a pellet of RNA. The
supernatant was aspirated and samples were washed with 0.7 mL cold 75 % ethanol,
vortexed, and placed in -20°C for at least one hour. Samples were then centrifuged at
10000 rpm for 10 minutes at 4°C, ethanol was removed, and RNA pellets were allowed
to dry for 5 minutes on ice. Finally, RNA was dissolved in 20 uL DEPC-water, RNA
concentration was measured by a Spectronic Genesys 10 Bio spectrophotometer, and
RNA integrity was checked by agarose gel electrophoresis.
Reverse Transcription
For each sample, 1 !lg of RNA was mixed with dNTPs and a random primer,
mixed, and held at 70°C in a thermal cycler for 5 minutes to melt secondary structure
within the RNA template. Then 5x buffer (Fisher), M-MLV reverse transcriptase
(Fisher), RNase inhibitor (Fisher) were added for a total volume of 20 IlL per reaction
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and samples were held at 42°C for a 1 hour extension step, followed by 10 minutes at
95°C to inactivate the reverse transcriptase enzyme. Resulting eDNA was diluted in 200
)..LL DEPC-water.
Real-Time Semi-Quantitative Polymerase Chain Reaction (RT-qPCR)
For each reaction, 10 )..LL of SYBR Green (Bio-Rad), 3 )..LL of nuclease-free water,
and 5 )..LL of eDNA were mixed with 2 )..LL of gene-specific primers. Samples were run in
a Stratagene MS3000P real-time PCR thermal cycler according to the protocol below
(Table 1). Relative mRNA levels were calculated using the comparative Ct method
(2AMC1). For all samples, P-actio was used as an internal reference control gene.
Sequences of gene-specific primers are listed in Table 2.
Table 1

Cycling Protocol for RT-qPCR.

Step

Temperature and Duration

N tunber of Cycles

Denaturation

95°C for 3 minutes

1 cycle

Amplification

95°C for 15 seconds
60°C for 30 seconds
72°C for 30 seconds

35 cycles

Final extension

95°C for 45 seconds
70°C for 30 seconds
95°C for 30 seconds

1 cycle
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Table 2

Sequences of Gene-specific Primers

Gene

Accession
Ntunber

~-actin

aSMA
SM22a
PECAM1
VE- cadherin
VEGF-R2
roouse HoxB5
human HoxB5

Forward Prirrer

NM_008268 CCTGCACTAACGGC
GACAG
NM_007392 GGACGTACAACTGG
TATTGTGC
NM_011526 AGGGATCGAAGCCA
GTGAAG
NM_008816 TGCACCCATCACTT
ACCACC
NM_009868 ATGAATCGCTGCCC
CACTATG
NM_010612 GCAAAACACTCACC
ATTCCCA
NM_008268 CCTGCACTAACGGC
GACAG
NM_002147 TCCTCGGAGCCTGA
GGAAGCGGCAAG

Reverse Prirrer

TGGCCTCGTCTATTTCG
GTGA
CGGCAGTAGTCACGAAG
GAAT
ACTGCTGCCATATCCTT
ACCT
CTTCATCCACCGGGGCT
ATC
CATTCCCTGTGTTAGCA
TCGAC
GAGGTTTGAAATCGACC
CTCG
TGGCCTCGTCTATTTCG
GTGA
CCCGTCCGGCCCGGTCA
TATCATG

Flow Cytometry Analysis of Cell Cycle and Protein Expression
Treated C3H/10Tl/2 cells were detached with trypsin, fixed with ethanol, blocked
with 2% BSA, and incubated with primary antibody at 1:100 dilution for either 2 hat
room temperature or overnight at 4 °C, followed by incubation with the secondary
antibody at 1:200 dilution for 1 h in the dark. Propidium iodide (PI, a DNA binding dye)
was added during the second antibody incubation for analysis of cell cycle profiles.
Samples were then analyzed using an Accuri C6 flow cytometer and Cflow software.
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CHAPTER IV
RESULTS
bFGF Stimulates Cell Proliferation
As reported in other studies (Ramasamy et al., 2012; Tsutsumi, 2001), we found
that treatment with bFGF stimulated proliferation of C3W10Tl/2 cells, as measured by
three different methods. First, we used a spectrophotometer to measure the optical
density of bFGF-treated and untreated cultures after staining with toluidine blue (Fig. 5).
Increased optical density of the treated culture indicates a higher number of cells relative
to untreated cells (Con).
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Figure 5. Spectrophotometric analysis of cell proliferation. Cells were grown in 1%
FBS MEM and treated with 10 ng/mL bFGF for 48h, then optical density was measured
with a spectrophotometer after the cells were stained with TB. The values are means±
SD (n =3, P < 0.05).

Next, we used flow cytometry to analyze the cell cycle profiles of treated and
untreated cells (Fig. 6). By treating the cells with the DNA-binding fluorescent dye
propidium iodide (PI), we measured the relative amounts of DNA in cells from treatment
and control groups. Cells inS and G2/M phases of the cell cycle have a higher DNA
content than cells in G 1 as they replicate their genomes in preparation for mitosis, and
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thus will have higher fluorescence (farther to the right on the x-axis) as measured by flow
cytometry. Figure 6 shows a higher proportion of cells in S and G2/M phases in the
bFGF-treated group than in the control group, indicating increased proliferation in
response to bFGF.
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Figure 6. Cell cycle analysis by flow cytometry. Cells were treated with 10 ng/mL
bFGF for 48h, then stained with propidium iodide, and flow cytometry was used to
measure fluorescence as an indicator of DNA content. The cell populations at different
phases of the cell cycle are indicated by bars.

Finally, we measured the expression of cyclin Dl as an indicator of proliferation.
Cyclin-dependent kinases (CDKs) and the cyclin proteins are major regulators that
control cell cycle progression. CDKs and cyclins form complexes that phosphorylate
numerous targets to allow progression through cell cycle checkpoints. While CDKs are
relatively stably expressed, cyclins are only expressed at specific times in the cell cycle,
which provides a mechanism to prevent uncontrolled cell growth. Thus, cyclin
expression can serve as an indicator of active proliferation. As seen in figure 7, bFGF-
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treated cells show increased cyclin D 1 mRNA levels relative to controls, which is
responsible for the increased cell proliferation.
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Figure 7. Analysis of cyclin D1 mRNA levels. Cells were treated with 10 ng/mL bFGF
for 48h and collected for RT-qPCR. The values are means ± SD (n = 3, P < 0.05).
bFGF Inhibits Mural Differentiation
Consistent with other reports in the literature (Papetti et al., 2003; Kawai-Kowase,
2004), we found that bFGF strongly inhibits transcription of the mural cell marker genes
smooth muscle a-actin (SMA) and SM22u (Fig. 8).
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Figure 8. Analysis of mural cell markers at mRNA level. Cells were treated with 10
ng/mL bFGF for 72h and collected for RT-qPCR. The values are means ± SD (n = 3, P <
0.01).
We then used flow cytometry to verify the downregulation of SMA at the protein
level. By incubating the cells with a primary antibody that binds to the SMA protein, and
then incubating with a secondary antibody that binds the primary antibody and is
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conjugated with a fluorophore (FITC), we fluorescently labeled the SMA protein in
treated and untreated cells, then analyzed the intensity of fluorescence (which correlates
with the expression level of SMA) in each group with a flow cytometer. As seen in
figure 9, the bFGF-treated group had lower fluorescence than the control group (left-shift
of bFGF-treated curve), confirming reduced expression of SMA at the protein level.
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Figure 9. Analysis of SMA protein levels. Cells were treated with 10 ng/mL bFGF for
48h, then fixed and incubated with SMA-specific antibodies and analyzed by flow
cytometry.

Next, we examined the expression of endothelial markers in response to bFGF
treatment. Untreated C3H/10T1/2 cells have extremely low baseline expression levels of
the endothelial markers PECAM-1 and VE-cadherin, and these levels were not
significantly increased after 9 days of treatment with bFGF (Fig. 10).
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Figure 10. Effects of bFGF on endothelial marker expression. Cells were treated with 5
ng/mL bFGF for 9 days and collected for RT-qPCR. The values are means± SD (n = 3, P
< 0 .01).
VEGF Treatment has no Significant Effects on Proliferation or Differentiation
VEGF is a major growth factor regulator of angiogenesis, and has been reported
to contribute to endothelial differentiation of MSCs in several studies (Oswald et al.,
2004; Wang et al., 2010). According to our results, treatment with VEGF alone did not
cause any significant effects on proliferation (Fig. 11) or expression of mural or
endothelial differentiation markers (Fig. 12).
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Figure 11. Effects of VEGF on proliferation. Cells were grown in 1% FBS MEM and
treated with 10 ng/mL VEGF for 48h, then optical density was measured with a
spectrophotometer after the cells were stained with TB. The values are means± SD (n =
3, p < 0 .05).
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Figure 12. Effects of VEGF on endothelial marker expression. Cells were treated with
10 ng/mL VEGF for 9 days and collected for RT-qPCR. The values are means± SO (n =
3, p < 0.01).

Treatment with bFGF+VEGF did not Stimulate Endothelial Differentiation
Following the protocol of Wang et al. (2010), we treated C3H/10Tl/2 cells with a
combination of bFGF and VEGF (5 ng/mL and 10 ng/mL, respectively) for 9 days. This
treatment was reported to induce endothelial differentiation in this cell line, but our
results show that the endothelial markers PECAM-1 and VE-cadherin are not
significantly upregulated at the transcriptional (Fig. 13) or protein levels (not shown), and
cells are morphologically similar to cells treated with bFGF alone (Fig. 14).
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Figure 13. Effects of combined treatment with bFGF and VEGF on differentiation
marker expression. Cells were treated with 5 ng/mL bFGF and 10 ng/mL VEGF for 9
days and collected for RT-qPCR. The values are means± SO (n = 3, P < 0.01).
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Figure 14. C3H/10Tl/2 cell morphology. Left panel, untreated cells. Middle panel, cells
treated with 10 ng/mL bFGF for 3 days. Right panel, cells treated with 5 ng/mL bFGF
and 10 ng/mL VEGF for 3 days .

Because of the apparent low responsiveness to VEGF, we decided to examine the
expression of Flld , the primary receptor for VEGF. In untreated cells, Flkl mRNA
levels were neglible, and treatment with bFGF, VEGF, or a combination of both over a 9
day course did not significantly increase Flkl transcription (Fig. 15) or protein levels
(Fig. 16).
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Figure 15. Effects of growth factor treatment on Flk1 expression. Cells were treated
with 5 ng/mL bFGF, 10 ng/mL VEGF, or a combination of both for 9 days and collected
for RT-qPCR. The values are means± SD (n = 3, P < 0.01).
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Figure 16. Analysis of Flk1 protein levels. Cells were treated with 10 ng/mL VEGF (red
curve) or left untreated (black curve) for 9 days, then fixed and incubated with Flk1specific antibodies and analyzed by flow cytometry.

HoxB5 Transfection did not Induce Flk1 Expression or Endothelial Differentiation
In order to promote endothelial differentiation, we attempted to induce expression
of Flk1 so that cells would be more responsive to VEGF. Toward this end, we
transfected C3H cells with HoxB5, a transcription factor that has been shown to bind to
an intronic enhancer region of the Flk1 gene and increase endothelial differentiation in
HoxB5-transfected embryonic stem cells (Wu, Moser, Bautch, & Patterson, 2003).
Although transfection was successful and HoxB5 was expressed at high levels, we did
not observe a significant increase in Flk1 transcription (Fig. 17). HoxB5 transfected cells
did show some upregulation of endothelial markers after growth factor treatment, but the
increases were not statistically significant and absolute expression levels remained
extremely low (Fig. 18).
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Figure 18. Effects of growth factor treatment on HoxB5-transfected cells. Cells were
treated with 5 ng/mL bFGF, 10 ng/mL VEGF, or a combination of both for 9 days, then
collected for RT-qPCR. The values are means± SD (n = 3, P < 0.01).

Finally, to verify that the HoxB5 gene we transfected was functional, we
transfected D3 embryonic stem cells and analyzed expression of HoxB5 and endothelial
markers. As seen in Figure 19, HoxB5 transfection resulted in increased transcription of
Flk1 , which is consistent other reports (Wu et al. , 2003).
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stem cells. Inset: RT-PCR result after gel electrophoresis. (-) and (+)represent
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CHAPTER V
DISCUSSION
The differentiation capacity of mesenchymal stem cells has not been fully
elucidated. MSCs classically give rise to cartilage, fat, and bone-producing cells, but
have also reportedly been differentiated to smooth and cardiac muscle cells, neurons, and
endothelial cells (Pinney & Emerson, 1989; Minguell et al. Conget, 2010; Wang et al.,
2010; Woodbury et al., 2000; Oswald et al. 2004). Endothelial cells typically develop
from an early precursor cell type called a hemangioblast, which gives rise to blood cells
as well as endothelial progenitor cells (Ferguson, Kelley, & Patterson, 2005). Although
the ontogeny of MSCs remains unclear, they are distinct from both hematopoietic stem
cells and endothelial progenitor cells, so reports of MSC differentiation to ECs deserve
further attention and clarification.
Several papers report in vivo differentiation of MSCs to ECs (Davani, et al., 2003;
Tang, et al., 2006), usually involving injection of DAPI-labeled MSCs into infarcted
cardiac tissue, then performing immunohistochemistry to characterize the phenotype of
labeled cells after several days or weeks. However, this experimental design does not
allow analysis of the molecular mechanisms that lead to endothelial differentiation.
There are a few reports of endothelial induction in vitro, including two that used the
C3W10Tl/2 cell line (Wang et al., 2005; Wang et al., 2010). One study used shear stress
as an induction stimulus (Wang et al., 2005). This result is not surprising, as shear forces
have been shown to have strong effects on cell morphology, gene expression, and
differentiation of endothelial progenitor cells (Yamamoto et al., 2003). Two studies
reported endothelial induction after treatment with angiogenic growth factors. Oswald et
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al. (2004) reported that human bone marrow-derived MSCs could be differentiated to
endothelial cells after treatment with high doses of VEGF, and Wang et al. (2010)
reported endothelial induction of C3H/10Tl/2 cells using a combination of bFGF and
VEGF. In the present study, we attempted to validate and expand on these reports by
analyzing the effects of individual angiogenic factors on differentiation to vascular cell
types.
We found that the two major effects of bFGF were to stimulate proliferation and
to inhibit mural differentiation markers such as a-SMA and SM22a. These effects have
been previously reported in C3H cells and other MSCs (Papetti et al. 2003; KawaiKowase, 2004), and are consistent with a role for bFGF as an inhibitor of mural
differentiation. The endothelial markers PECAM-1 and VE-cadherin are not expressed
in untreated C3H cells, and bFGF did not induce significant transcription of these genes.
Although VEGF is a major regulator of vascular development, and is used as a
stimulus in almost all reports of endothelial differentiation of MSCs, we did not observe
any significant effects on proliferation or transcription of mural or endothelial
differentiation markers after 9 days of stimulation with VEGF. Because naive
C3H/10Tl/2 cells express mural cell markers at relatively high levels-indeed, these
cells are often used as de facto mural cells in coculture with endothelial cells for
modeling angiogenesis-it is possible that VEGF is not able to easily overcome this
inherent mural character. It was thought that the addition of bFGF to the protocol to
inhibit mural cell markers and de-differentiate the cells might enhance VEGF-induced
endothelial induction. Following the protocol of Wang et al. (2010), we treated cells with
a combination of 5 ng/mL bFGF and 10 ng/mL VEGF for 9 days. The effects were
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similar to treatment with bFGF alone: increased proliferation and decreased transcription
of mural cell makers, with no induction of endothelial markers. Because the effects of
bFGF seemed to predominate when both factors were used simultaneously, we also tried
a step-wise treatment method, in which cells were pre-treated with bFGF for 48h before
treatment with VEGF or a VEGF+bFGF combination, but we obtained results similar to
those of simultaneous treatment (data not shown).
The apparent inablility of these cells to respond to VEGF could be attributable to
the lack of expression of Flkl (a.k.a. VEGFR2), the major cell surface receptor for
VEGF. Despite the use of VEGF in many studies on MSCs, most published expression
profiles show that MSCs, including C3H/10Tl/2 cells, do not express VEGF receptors.
One paper reports that VEGF can bind to and activate the surface receptor for the closely
related platelet-derived growth factor (PDGF), which is expressed in MSCs (Ballet al.,
2007); however, the intracellular effects of this activation would presumably be identical
to those of PDGF, which is not involved in endothelial differentiation.
To determine whether Flk1 is in fact the missing link in the capacity for
endothelial differentiation of C3H cells, we attempted to induce Flk1 by expressing the
transcription factor HoxB5. This protein has been reported to bind to an intronic
enhancer region of the Flk1 gene and increase Flk1 expression in embryonic stem cells
(Wu et al. 2003). Although we successfully transfected the cells with HoxB5 (Fig. 17),
we did not observe any increase in Flk1 transcription after real-time PCR analysis.
However, when PCR products were were subjected to gel electrophoresis, a very faint
band of the expected size for Flk1 amplicons was visible in transfected cells (Fig. 17,
inset), indicating that some low-level induction did occur. It may be that the Flk1 gene in
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C3H/10Tl/2 cells is mostly unavailable for HoxB5 binding (or binding of other necessary
transcription factors) due to epigenetic modifications such as DNA methylation or
histone modifications. Consistent with this theory, we found that HoxB5 did increase
Flkl transcription in D3 ESCs, which are undifferentiated and thus should not be
epigenetically restricted in terms of differentiation capacity. Cell reprogramming
methods, such as those used to generate iPSCs (Takahashi & Yamanaka, 2006), generally
involve the use of master regulatory transcription factors that reset genome-wide DNA
methylation patterns, causing a reversion to an undifferentiated state. In this case, it
seems that the change from MSC to endothelial lineage may be too drastic to be induced
by our methods.
In conclusion, our results indicate that C3H/10Tl/2 cells do not differentiate to
endothelial cells in vitro in response to two prototypical angiogenic factors. It seems that
this cell line is intrinsically closer to a mural cell phenotye. Simple stimulation with
bFGF and VEGF is unable to cause transdifferentiation to the endothelial lineage, even in
the cells expressing HoxB5, which upregulates Flkl in embryonic stem cells. While
C3H/10T 112 cells theoretically have the potential to differentiate into endothelial cells,
that will need a more rigorous reprogramming strategy that involves manipulating
multiple transcription factors driving endothelial cell differentiation.
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